Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

14.51 -8.19 (-36.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,675,960
Open 15.78
Bid (Size) 14.41 (100)
Ask (Size) 14.51 (800)
Prev. Close 22.70
Today's Range 13.80 - 16.00
52wk Range 16.00 - 34.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill

Performance

YTD
-27.4%
-27.4%
1 Month
-47.2%
-47.2%
3 Month
-49.3%
-49.3%
6 Month
-23.6%
-23.6%
1 Year
-24.5%
-24.5%

More News

Read More
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts ↗
Via Chartmill
Topics Earnings
Oculis Holding AG (NASDAQ:OCS) Reports Q4 2025 Earnings Beat, Focus Remains on 2026 Clinical Catalysts ↗
Via Chartmill
Topics Earnings
News headline image
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals ↗
Via MarketBeat
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q1 2026 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
From Oculis Holding AG
Via GlobeNewswire
News headline image
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Katie Kazem as Chief Legal Officer
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 14.51
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 06/01/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS